In a single-arm Phase II study, a regimen consisting of avelumab (a monoclonal PD-L1 antibody) and axitinib (a tyrosine kinase inhibitor targeted against multiple VEGF receptors) was prescribed to patients with recurrent glioblastoma. This evidence concerns the gene CD274 and glioblastoma.